Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients

Scandinavian Journal of Pain

Volumn 1, Issue 1, 2010, Pages 24-33

  Lemberg, K K ^a   Heiskanen, T E ^b   Neuvonen, M ^b   Kontinen, V K ^a,b   Neuvonen, P J ^b   Dahl, M L ^c   Kalso, E A ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Analgesia; Chronic pain; Noroxycodone; Noroxymorphone; Oxycodone; Oxymorphone; Paroxetine

Indexed keywords

ALENDRONIC ACID; AMITRIPTYLINE; AMLODIPINE; CHLORDIAZEPOXIDE; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ETORICOXIB; FUROSEMIDE; GABAPENTIN; HALOPERIDOL; IBUPROFEN; METOCLOPRAMIDE; MIRTAZAPINE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PAROXETINE; PHENOXYBENZAMINE; PREGABALIN; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GENOTYPE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; PAIN ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 72049114957     PISSN: 18778860     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjpain.2009.09.003     Document Type: Article

References (56)

1. Aqua K., Gimbel J.S., Singla N., Ma T., Ahdieh H., and Kerwin R. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther 29 (2007) 1000-1012
2. Backlund M., Lindgren L., Kajimoto Y., and Rosenberg P.H. Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anaesth 9 (1997) 30-35
3. Beaver W.T., Wallenstein S.L., Houde R.W., and Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17 (1977) 186-198
4. Bloomer J.C., Woods F.R., Haddock R.E., Lennard M.S., and Tucker G.T. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33 (1992) 521-523
5. Boström E., Simonsson U.S., and Hammarlund-Udenaes M. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 94 (2005) 1060-1066
6. Boström E., Simonsson U.S., and Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat-indications for active influx and implications for PK/PD. Drug Metab Dispos 34 (2006) 1624-1631
7. Boström E., Hammarlund-Udenaes M., and Simonsson U.S. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 108 (2008) 495-505
8. Brøsen K., Gram L.F., and Kragh-Sørensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. Ther Drug Monit 13 (1991) 177-182
9. Campa D., Gioia A., Tomei A., Poli P., and Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83 (2008) 559-566
10. Caraco Y., Sheller J., and Wood A.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 278 (1996) 1165-1174
11. Chen Z.R., Irvine R.J., Somogyi A.A., and Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48 (1991) 2165-2171
12. Curtis G.B., Johnson G.H., Clark P., Taylor R., Brown J., O'Callaghan R., et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55 (1999) 425-429
13. Dayer P., Desmeules J., Leemann T., and Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufl). Biochem Biophys Res Commun 152 (1988) 411-416
14. Dobbins S., Brown N.O., and Shofer F.S. Comparison of the effects of buprenorphine, oxymorphone hydrochloride, and ketoprofen for postoperative analgesia after onychectomy or onychectomy and sterilization in cats. J Am Anim Hosp Assoc 38 (2002) 507-514
15. Hagelberg N.M., Nieminen T.H., Saari T.I., Neuvonen M., Neuvonen P.J., Laine K., et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65 (2009) 263-271
16. Hassan H.E., Myers A.L., Lee I.J., Coop A., and Eddington N.D. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 96 (2007) 2494-2506
17. Heiskanen T., and Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 73 (1997) 37-45
18. Heiskanen T., Olkkola K.T., and Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64 (1998) 603-611
19. Hersberger M., Marti-Jaun J., Rentsch K., and Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46 (2000) 1072-1077
20. Kalso E., Vainio A., Mattila M.J., Rosenberg P.H., and Seppälä T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67 (1990) 322-328
21. Kalso E., Pöyhiä R., Onnela P., Linko K., Tigerstedt I., and Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35 (1991) 642-646
22. Karunatilake H., and Buckley N.A. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother 40 (2006) 155-157
23. Lalovic B., Phillips B., Risler L.L., Howald W., and Shen D.D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32 (2004) 447-454
24. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., and Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79 (2006) 461-479
25. Laugesen S., Enggaard T.P., Pedersen R.S., Sindrup S.H., and Brøsen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77 (2005) 312-323
26. Lee H.K., Lewis L.D., Tsongalis G.J., McMullin M., Schur B.C., Wong S.H., et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367 (2006) 196-200
27. Lemberg K.K., Kontinen V.K., Siiskonen A.O., Viljakka K.M., Yli-Kauhaluoma J.T., Korpi E.R., et al. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105 (2006) 801-812
28. Leow K.P., Smith M.T., Williams B., and Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52 (1992) 487-495
29. Letrent S.P., Pollack G.M., Brouwer K.R., and Brouwer K.L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27 (1999) 827-834
30. Mirghani R.A., Sayi J., Aklillu E., Allqvist A., Jande M., Wennerholm A., et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 16 (2006) 637-645
31. Monory K., Greiner E., Sartania N., Sallai L., Pouille Y., Schmidhammer H., et al. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 64 (1999) 2011-2020
32. Nieminen T.H., Hagelberg N.M., Saari T.I., Pertovaara A., Neuvonen M., Laine K., et al. Rifampin greatlyreduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110 (2009) 1371-1378
33. Odrcich M., Bailey J.M., Cahill C.M., and Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 120 (2006) 207-212
34. Osborne R., Joel S., Trew D., and Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47 (1990) 12-19
35. Otton S.V., Inaba T., and Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34 (1984) 73-80
36. Peckham E.M., and Traynor J.R. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316 (2006) 1195-1201
37. Petraglia F., Facchinetti F., Parrini D., Micieli G., De Luca S., and Genazzani A.R. Simultaneous circadian variations of plasma ACTH, beta-lipotropin, beta-endorphin and cortisol. Horm Res 17 (1983) 147-152
38. Poulsen L., Brøsen K., Arendt-Nielsen L., Gram L.F., Elbaek K., and Sindrup S.H. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51 (1996) 289-295
39. Pöyhiä R., Olkkola K.T., Seppälä T., and Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 32 (1991) 516-518
40. Pöyhiä R., Seppälä T., Olkkola K.T., and Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33 (1992) 617-621
41. Rang S.T., and Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth 55 (2008) 521-525
42. Rosebraucgh C.J., Flockhart D.A., Yasuda S.U., and Woosley R.L. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol 41 (2001) 224-227
43. Schinkel A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36 (1999) 179-194
44. Silvasti M., Rosenberg P., Seppälä T., Svartling N., and Pitkänen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 142 (1998) 576-580
45. Sindrup S.H., Gram L.F., Brøsen K., Eshoj E., and Mogensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42 (1990) 135-144
46. Sindrup S.H., Brøsen K., Gram L.F., Hallas J., Sjelbo E., Allen A., et al. The relation between paroxetine and sparteine oxidation polymorphism. Clin Pharmacol Ther 51 (1992) 278-287
47. Steijns L.S., and Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44 (1998) 914-917
48. Thompson S.J., Koszdin K., and Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92 (2000) 1392-1399
49. Thompson C.M., Wojno H., Greiner E., May E.L., Rice K.C., and Selley D.E. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther 308 (2004) 547-554
50. van Schaik R.H., de Wildt S.N., van Iperen N.M., Uitterlinden A.G., van den Anker J.N., and Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46 (2000) 1834-1836
51. van Schaik R.H., de Wildt S.N., Brosens R., van Fessem M., van den Anker J.N., and Lindemans J. The CYP3A4*3 allele: is it really rare?. Clin Chem 47 (2001) 1104-1106
52. van Schaik R.H., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48 (2002) 1668-1671
53. Wang A., Yu B.N., Luo C.H., Tan Z.R., Zhou G., Wang L.S., et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60 (2005) 843-848
54. Weinstein S.H., and Gaylord J.C. Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 68 (1979) 527-528
55. Yanagidate F., and Dohi S. Epidural oxycodone or morphine following gynaecological surgery. Br J Anaesth 93 (2004) 362-367
56. Zwisler S.T., Enggaard T.P., Noehr-Jensen L., Pedersen R.S., Mikkelsen S., Nielsen F., et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104 (2009) 335-344